Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Syros to Participate in Upcoming Investor Conferences By: Syros Pharmaceuticals via Business Wire May 07, 2024 at 09:00 AM EDT Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows: JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Wednesday, May 29 Presentation Time: 1:00 p.m. ET Location: Virtual To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation. About Syros Pharmaceuticals Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/Contacts Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com Investor Contact Amanda Isacoff Stern Investor Relations, Inc. 212-362-1200 amanda.isacoff@sternir.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Syros to Participate in Upcoming Investor Conferences By: Syros Pharmaceuticals via Business Wire May 07, 2024 at 09:00 AM EDT Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows: JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Wednesday, May 29 Presentation Time: 1:00 p.m. ET Location: Virtual To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation. About Syros Pharmaceuticals Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/Contacts Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com Investor Contact Amanda Isacoff Stern Investor Relations, Inc. 212-362-1200 amanda.isacoff@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows: JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New York, NY TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Wednesday, May 29 Presentation Time: 1:00 p.m. ET Location: Virtual To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation. About Syros Pharmaceuticals Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/
Syros Contact Karen Hunady Director of Corporate Communications & Investor Relations 1-857-327-7321 khunady@syros.com Investor Contact Amanda Isacoff Stern Investor Relations, Inc. 212-362-1200 amanda.isacoff@sternir.com